{
    "nct_id": "NCT05301842",
    "official_title": "A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab Â± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-3)",
    "inclusion_criteria": "* No evidence of extrahepatic disease\n* Disease not amenable to curative surgery or transplantation or curative ablation but disease amenable to TACE\n* Child Pugh score class A\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment\n* Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria\n* Adequate organ and marrow function\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 120 Years",
    "exclusion_criteria": "* History of symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardia arrhythmia\n* History of hepatic encephalopathy\n* Major portal vein thrombosis visible on baseline imaging\n* Uncontrolled arterial hypertension\n* Co-infection with HBV and HDV",
    "miscellaneous_criteria": ""
}